We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+29.16%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$2.01B
AUM Growth
+$536M
Cap. Flow
+$287M
Cap. Flow %
14.23%
Top 10 Hldgs %
41.55%
Holding
100
New
24
Increased
34
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$52.5M
2
MDT icon
Medtronic
MDT
+$51M
3
ISRG icon
Intuitive Surgical
ISRG
+$45.3M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$37.4M
5
DXCM icon
DexCom
DXCM
+$32.3M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$63.9M
2
THC icon
Tenet Healthcare
THC
+$40.4M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$30.1M
4
BTSG icon
BrightSpring Health Services
BTSG
+$13.4M
5
PFE icon
Pfizer
PFE
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
26
Merck
MRK
$322B
$26.3M 1.31%
+250,000
New +$23.5M
ALNY icon
27
Alnylam Pharmaceuticals
ALNY
$29.6B
$23.9M 1.18%
60,000
– –
IRTC icon
28
iRhythm Holdings
IRTC
$4.02B
$23.1M 1.15%
130,000
+65,000
+100% +$11.5M
QURE icon
29
uniQure
QURE
$3.12B
$21.5M 1.07%
900,000
+300,000
+50% +$11.6M
LLY icon
30
Eli Lilly
LLY
$1.08T
$21.5M 1.07%
20,000
– –
BSX icon
31
Boston Scientific
BSX
$74.2B
$21.5M 1.07%
225,000
-75,000
-25% -$7.35M
NBIX icon
32
Neurocrine Biosciences
NBIX
$16.5B
$21.3M 1.06%
150,000
– –
LFST icon
33
Lifestance Health
LFST
$4.39B
$21.1M 1.05%
3,000,000
+1,500,000
+100% +$9.05M
ELV icon
34
Elevance Health
ELV
$84.7B
$21M 1.04%
60,000
+10,000
+20% +$3.38M
UPB
35
Upstream Bio Inc
UPB
$386M
$20.4M 1.01%
750,000
+175,000
+30% +$4.36M
THC icon
36
Tenet Healthcare
THC
$20.9B
$19.9M 0.99%
100,000
-200,000
-67% -$40.4M
ASND icon
37
Ascendis Pharma A/S
ASND
$16.7B
$19.2M 0.95%
90,000
+30,000
+50% +$6.2M
ROIV icon
38
Roivant Sciences
ROIV
$25.5B
$18.4M 0.92%
850,000
+100,000
+13% +$1.97M
DOCS icon
39
Doximity
DOCS
$4.65B
$17.7M 0.88%
400,000
+220,000
+122% +$12.3M
BIIB icon
40
Biogen
BIIB
$30.1B
$17.6M 0.87%
+100,000
New +$16.3M
RGNX icon
41
Regenxbio
RGNX
$703M
$17.3M 0.86%
1,200,000
+100,000
+9% +$1.25M
TERN
42
DELISTED
Terns Pharmaceuticals
TERN
$17.2M 0.85%
425,000
-525,000
-55% -$12.1M
BHVN icon
43
Biohaven
BHVN
$2.18B
$16.9M 0.84%
1,500,000
+850,000
+131% +$10.5M
UNH icon
44
UnitedHealth
UNH
$365B
$16.5M 0.82%
+50,000
New +$16.9M
TARS icon
45
Tarsus Pharmaceuticals
TARS
$3.05B
$16.4M 0.81%
200,000
-50,000
-20% -$3.73M
FMS icon
46
Fresenius Medical Care
FMS
$12.7B
$15.5M 0.77%
650,000
+200,000
+44% +$4.97M
BEAM icon
47
Beam Therapeutics
BEAM
$2.77B
$15.2M 0.76%
550,000
+150,000
+38% +$3.83M
SLNO
48
DELISTED
Soleno Therapeutics
SLNO
$15M 0.75%
+325,000
New +$17.8M
RDNT icon
49
RadNet
RDNT
$6B
$14.3M 0.71%
200,000
-100,000
-33% -$7.72M
SRRK icon
50
Scholar Rock
SRRK
$6.34B
$13.2M 0.66%
300,000
+200,000
+200% +$7.5M
1
2
3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Integral Health Asset Management held 100 positions worth $2.01B, up 36% from $1.48B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Integral Health Asset Management deployed $287M of net new capital in Q4 2025, opening 24 new positions and adding to 34 existing holdings. Its largest new stake was DexCom: 500,000 shares worth $33.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $63.9M trimmed.

  • Integral Health Asset Management's largest Q4 2025 buy was DexCom: 500,000 shares worth $33.2M.
  • Integral Health Asset Management added most to Revolution Medicines in Q4 2025, an estimated $52.5M increase.
  • Integral Health Asset Management's biggest Q4 2025 reduction was Insmed, cutting an estimated $63.9M.
  • Integral Health Asset Management fully exited Pfizer in Q4 2025, selling an estimated $12.7M.
  • Integral Health Asset Management's ten largest holdings make up 42% of its $2.01B portfolio in Q4 2025.
  • Integral Health Asset Management opened 24 new positions and closed 14 in Q4 2025.
  • Integral Health Asset Management's portfolio value rose 36% quarter-over-quarter to $2.01B.

Based on Integral Health Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.